Structural Features and Classification
Chemically, daclizumab (Daclizumabum) is classified as a humanized monoclonal antibody. The molecule combines 90% human-derived protein sequences with 10% murine components. This hybrid structure ensures the necessary binding specificity.
Mechanism of Action
The primary pharmacological role is to target specific components of the immune system:
- The drug selectively binds to interleukin-2 (IL-2) receptors.
- It targets exclusively activated T lymphocytes.
- It effectively blocks the activation of the cell-mediated immune response, which is critical during organ transplantation.
Pharmacokinetics and Administration Regimen
The drug is administered parenterally following a strict dosing schedule:
- Route of administration: Intravenous only.
- Course of therapy consists of 5 consecutive doses.
- The first dose is administered exactly 24 hours before the transplantation procedure.
- Subsequent doses are given at fixed 14-day intervals.
- A single course provides prolonged receptor blockade lasting up to 120 days.
Safety Profile and Adverse Effects
Overall, daclizumab is characterized as a relatively non-toxic medication. However, various adverse reactions may occur during pharmacotherapy:
- Gastrointestinal: Digestive system disturbances predominate.
- Systemic manifestations: Headache, fever (pyrexia), prominent tremor, and sleep disturbances (insomnia) may occur.
- Cardiovascular effects: Blood pressure fluctuations (hypertension or hypotension), tachycardia, and lower extremity or pulmonary edema.
- Other reactions: Risk of infectious complications, dyspnea, hyperglycemia, and musculoskeletal pain (myalgia and arthralgia).